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Introduction: Repair of large bone defects remains a significant clinical challenge. Bone marrow stromal cells
(BMSCs), a subset of which is known as bone marrow-derived mesenchymal stem cells, show therapeutic potential
for bone regeneration. However, their isolation, expansion and implantation will need to be conducted under good
manufacturing practices (GMP) at separate locations. An investigation which mimics this clinical scenario where
large bone defects shall be regenerated is required before clinical trials can be initiated.
Methods: Seven batches of 100 million human ex-vivo expanded BMSCs from five donors were transported fresh in
syringes from a GMP facility in Germany to France. BMSCs were mixed with biphasic calcium phosphate (BCP)
biomaterial prior to subcutaneous implantation in nude mice. The capacity of BMSCs in unison with BCP to
regenerate critical sized cranial bone defects was also evaluated. BMSCs expressing luciferase were used to assess
the viability and bio-distribution of implanted cells. In situ hybridization, using the human-specific repetitive Alu
sequence, was performed for the identification of human cells in explants.
Results: Eight weeks after implantation of BMSCs, mineralized bone containing mature bone marrow territories was
formed in ectopic sites and in calvaria defects. Significant loss of cell viability was observed by bioluminescence
imaging and only 1.5 percent of the initial number of transplanted cells remained after 37 days. After eight weeks,
while explants were comprised primarily of host cells, there were also human cells attached along the periphery of
BCP and embedded in osteocyte lacunae dispersed throughout the newly formed bone matrix.
Conclusions: This study demonstrates the safety and efficacy of BMSC/BCP combinations and provides crucial
information for the implementation of BMSC therapy for bone regeneration.Introduction
Successful repair of bone defects caused by trauma, cancer
or metabolic diseases remains a significant clinical challenge
for reconstructive surgeons. Bone is the most frequently
transplanted tissue, with 2.2 million bone replacement
procedures conducted globally each year [1]. Autolo-
gous bone transplantation is limited by the quantity and
quality of grafted bone and can lead to complications at
the second surgical site, while allogenic bone grafts pose
the risk of disease transfer and immunologic rejection.* Correspondence: pierre.layrolle@inserm.fr
1INSERM, UMR957, Laboratory of the Pathophysiology of Bone Resorption, Faculty
of Medicine, 1 Rue Gaston Veil, 44035, University of Nantes, Nantes, France
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unless otherwise stated.Consequently, there are considerable incentives for de-
veloping alternative solutions for bone regeneration.
Significant opportunities exist for tissue engineering
strategies in orthopedic and maxillofacial surgery. Synthetic
biomaterial scaffolds in association with bone marrow stro-
mal cells (BMSCs), a subset of which is known as bone
marrow-derived mesenchymal stem cells, could overcome
the limitations of biological bone grafts. BMSCs are multi-
potent progenitor cells, capable of differentiating into oste-
oblasts, chondrocytes and adipocytes [2], and are therefore
considered promising for tissue engineering applications.
Human BMSCs can be isolated from a small volume of
bone marrow aspiration under local anesthesia. However,
due to the diminutive number of BMSCs in bone marrow
(0.001 to 0.01% of bone marrow mononuclear cellsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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clinically transplantable doses. Since BMSCs are deemed
an advanced therapy medicinal product by the European
Commission [4], they must be produced in accordance
with good manufacturing practice (GMP). Safe, robust and
GMP-compliant protocols for large-scale isolation and
expansion of BMSCs, which avoid animal products such as
fetal calf serum by using human platelet lysate (PL), have
been developed [5-8]. Published data identified transform-
ing growth factor beta-1, vascular endothelial growth
factor, platelet-derived growth factor, fibroblast growth
factor and epidermal growth factor among effectors of PL
activity [5,9]. Furthermore, it has been demonstrated pre-
viously that PL is a safe alternative to fetal calf serum for
culturing human BMSCs and that it favors both osteo-
blastic differentiation and bone tissue formation [6,10].
The capacity of BMSCs for bone repair has been studied
in vivo with promising results [11-13]. However, for clinical
relevance it is clear that the isolation, expansion and
implantation of cells will need to be conducted at separate
facilities, often with considerable distances between the cell
production site and the surgical room. Cryopreserved
BMSCs maintain their bone formation capabilities [14].
However, the transportation of frozen cells directly to the
operating theater is not feasible because of the time re-
quired for cells to recover function after thawing [15] and
the potential adverse effects of the cryoprotectants [16].
Veronesi and colleagues have recently determined that
when freshly harvested BMSCs are suspended in a saline/
human serum albumin (HSA) solution, cell viability is
maintained and bone formation in small-scale implants
can be achieved [17]. Nevertheless, there is a need to evalu-
ate the bone regeneration of BMSCs that have undergone
large-scale GMP expansion and transportation to a separ-
ate facility in clinically relevant numbers and time frames.
Determining the cell dose of BMSCs required for ad-
equate bone and hematopoiesis formation is of immense
interest for bone tissue engineering. While it might be
expected that higher numbers of cells would lead to in-
creased bone formation, Mankani and colleagues have
demonstrated a threshold beyond which more trans-
planted cells do not lead to more bone formation [12].
Adequate biomaterial scaffolds are required for the
transplantation of BMSCs targeted at repairing osseous
defects. BMSCs combined with porous calcium phos-
phate ceramics, namely hydroxyapatite/beta-tricalcium
phosphate, have been shown to induce bone formation
in the subcutis of nude mice [12,18,19] and in femoral
defects in rats [20]. Biphasic calcium phosphate (BCP)
biomaterials are widely used for bone augmentation, for
filling bone defects in combination with autologous bone
marrow, or for supplementing autologous bone grafts.
A further requirement for an advanced therapy medi-
cinal product prior to entering clinical trials is thedemonstration of the bio-distribution of the transplanted
BMSCs. There are conflicting observations as to the fate
of BMSCs transplanted within biomaterial scaffolds and
whether the newly formed bone is of host or donor cell
origin. Evidence for donor BMSCs being involved in
bone regeneration comes from studies that demonstrate
osteoblasts and osteocytes of donor origin within newly
formed bone [13,21,22]. Less donor cells were present in
later harvest transplants than at earlier time points,
however [22]. Conversely, Tasso and colleagues demon-
strated that donor BMSCs disappeared from the scaffold
after the second week of implantation and the newly
formed bone was entirely of host origin [23]. Studies
assessing implanted cell survival have shown substantial
death of implanted donor cells [24,25]. One study revealed
that 50% of initial donor BMSCs remained 48 hours after
implantation, while 5% remained after 8 weeks [24]. An-
other study showed that less than 1% was detectable after
30 days [25]. An investigation of the real-time metabolic
activity of transplanted cells and the cell origin of bone
formation would therefore shed light on whether bone is
formed directly by donor cells, or whether a paracrine
effect induces a host stromal cell response.
The first objective of this study was to determine the
optimal cell dosage required for bone formation before
scaling up to relevant clinical numbers of BMSCs. The
study sought to transport freshly produced BMSCs from
a GMP facility, where they were isolated and expanded,
to another site where they were mixed with biomaterial
and implanted, mimicking as much as possible the clin-
ical scenario where large bone defects of 5 to 10 cm3
shall be regenerated. The objectives were to quantify the
degree of ectopic bone and hematopoietic compartment
formation, as well as bone regeneration in critical-sized
defects in nude mice. A final premise of this study was
to explore the cell fate and biological activity of trans-
planted human BMSCs and to determine whether newly
formed bone was of host or donor origin.Methods
Biomaterial
BCP, a ceramic composed of hydroxyapatite/beta-trical-
cium phosphate in a ratio of 20/80 by weight, was used
because this composition has previously demonstrated
bone induction [19]. BCP granules, ranging in size from 1
to 2 mm, were supplied by Biomatlante (Vigneux de
Bretagne, France) under the brand name MBCP+. MBCP+
is CE and US Food and Drug Administration 510(k) ap-
proved as a synthetic bone substitute. BCP discs, 7 mm in
diameter and 2 mm in thickness, were used for calvaria re-
generation. The overall porosity (%vol) was 75 ± 5%, with
a pore size distribution of 70% (0 to 10 μm), 20% (10 to
100 μm) and 10% (100 to 300 μm). The BCP biomaterials
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sterilized at 25 kGray.
Isolation, expansion and characterization of clinical
batches of GMP-grade BMSCs
Bone marrow aspirates were obtained from the iliac crest,
by standard puncture and aspiration, of healthy human
donors (21 to 26 years old) after receiving informed
consent according to the Declaration of Helsinki. The
project was approved by the Ethical Committee of Ulm
University. A maximum of 37 ml bone marrow was aspi-
rated using up to four 20 ml Omnifix syringes (B. Braun,
Melsungen, Germany) and transplant aspiration needles
(Somatex, Teltow, Germany). Each syringe was prefilled
with 1,000 IU heparin in 2 ml NaCl (B. Braun). BMSCs
used in this study are of GMP grade and were expanded
according to previously published protocols [6]. In brief,
BMSCs were isolated from heparinized bone marrow
aspirates by seeding 50,000 white blood cells/cm2 on
two-chamber CellStacks (Corning/VWR, Ulm, Germany)
in alpha minimum essential medium (Lonza, Basel,
Switzerland) supplemented with 5% GMP-grade human
platelet lysate (IKT, Ulm, Germany) in order to avoid animal
products [5]. Cells were cultured for 10 or 14 days with
medium exchange twice per week. Cells were detached and
reseeded at a density of 4,000 BMSCs/cm2 on two-chamber
CellStacks in alpha minimum essential medium supple-
mented with 8% PL for a further 5 or 7 days. A production
license for this protocol has been granted from the
regional government (Regierungspräsidium Tübingen,
Germany; production and import license: DE_BW_01_
MIA_2013_0040/DE_BW_01_IKT Ulm). To assess the
quality of the aspirates, measures such as colony-forming
units (CFUs-F), BM-MNC content and doubling times
were measured. For phenotypic characterization, flow
cytometry was performed as described previously [5,6].
Fluorescent intensities of 50,000 to 100,000 BMSCs were
acquired. Briefly, BMSCs were stained for 15 minutes in
100 μl phosphate-buffered saline using the following com-
binations of antibodies: IgG-FITC (clone X40), IgG-PE
(clone X40), IgG-PerCP (clone X40); CD90-FITC (clone
5E10), CD34-PE (clone 8G12), CD45-PerCP (clone 2D1);
CD105-FITC (clone SN6), CD73-PE (clone AD2), CD3-
PerCP (clone SK7); and HLA-DR,DQ,DP-FITC (clone
Tü39), HLA-A,B,C-PE (clone G46-2.6). All antibodies
were sourced from Becton Dickinson (Heidelberg,
Germany), except CD105 that was from AbDSerotec
(Puchheim, Germany). After washing with phosphate-
buffered saline, cells were analyzed using a BD FACScan
(BD Biosciences, Heidelberg, Germany).
Differentiation capacity of expanded BMSCs was per-
formed as described previously [5,6]. Briefly, BMSCs differ-
entiation was induced using adipogenic differentiation
medium from Lonza or chondrogenic or osteogenicdifferentiation media from Miltenyi (Bergisch Gladbach,
Germany) according to the manufacturers’ instructions. For
detection of adipogenic differentiation, cells were stained
with Oil Red O solution in 2-propanol, diluted to 60% using
deionized water. Chondrogenic differentiation was detected
by Alcian Blue staining, while mineralization was detected
by Alizarin red staining.
Cell numbers required for bone formation
Prior to the transportation of large batches of fresh
BMSCs for bone repair, it was necessary to quantify the
optimal dose of cells for bone formation in proportion-
ally lower numbers. Different quantities of BMSCs in
passage 2 from three different human donors were
mixed with 50 mg BCP particles and allowed to attach
for 1 hour prior to subcutaneous implantation in nude
mice. Number of cells per implant and number of im-
plants per group were as follows: 0 cells, n =5; 0.1 × 106
cells, n =9; 2 × 106 cells, n =9; and 4 × 106 cells, n =9.
Transportation of fresh bone marrow stromal cells
Cells were harvested and washed, and 100 × 106 passage 1
BMSCs from each of the five donors were suspended in
7 ml saline solution supplemented with 4%, 5% or 20%
HSA solution (CSL Behring, Hattersheim am Main,
Germany) in a sterile luer lock 20 ml syringe (B. Braun).
Cells were transported within 24 hours from Ulm (Baden-
Wurttemberg, Germany) to Nantes (Pays de la Loire,
France) at 20°C via TNT Express overnight courier. Upon
arrival, cell viability was confirmed using the trypan blue
exclusion method. Each syringe containing BMSCs was
connected to a syringe containing 5 cm3 BCP particles
(2.5 g) using a double luer lock. Cells were allowed to attach
to the BCP particles for 1 hour, prior to implantation in
nude mice. Cell attachment was confirmed by methylene
blue staining.
Bone marrow stromal cell/biomaterial implantation in the
subcutis and calvaria of nude mice
All animal experiments were performed according to
Directive 2010/63/UE and after approval of protocols from
the local ethical committee (CEEA, Pays-de-la-Loire,
France). Immunocompromised female mice (RjOrl: NMRI-
Foxn1nu/Foxn1nu) were purchased from a professional
breeder (Janvier Labs, Saint-Berthevin, France) at 4 weeks of
age. Mice were placed in cages as groups of five in HEPA-
filtered closets with water and food ad libitum, and were
quarantined for a minimum of 10 days prior to surgery.
Once under general anesthesia by inhalation of isoflurane,
the skin was disinfected with 1% iodine alcoholic solution.
For subcutaneous implants, BCP granules alone (BCP) or
in association with BMSCs (BCP + BMSCs) were implanted
on the dorsal side in two subcutis pockets that were created
by skin incisions and tissue dilacerations with sterile
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BCP were implanted per subcutaneous site in randomly
assigned nude mice. BMSCs from five donors that were
transported were implanted subcutaneously: Donor 1, n =6;
Donor 2, n =6; Donor 3, n =4; Donor 4, n =8; and Donor 5,
n =7.
For calvaria implants, the mouse was maintained on a
stereostatic frame and a skin incision of 1 cm was made
to expose the skull. A critical-sized defect 4 mm in
diameter was created in the calvaria bone [26] using a
trephine and a dental micromotor (Nouvag NM3000;
NOUVAG, Goldach, Switzerland). Constant saline irriga-
tion was used during drilling. Then 3 × 106 BMSCs in
passage 2 or 3 were seeded onto one side of a BCP disc
1 hour prior to implantation. Cells from three different
human donors were used. Discs were overlain cell-side
down over the calvaria defect. Calvaria defects overlain
with BCP discs alone or defects that were left empty
served as controls. Skin incisions were closed with su-
tures (Filapeau; Peters Surgical, Bobigny, Ile-de-France,
France). Analgesic (20 μg/kg; Buprenorphine, Axience,
France) was injected intramuscularly before surgery and
every 8 hours for 3 days after surgery. Animals were ob-
served daily and body weights were determined weekly.
After 4 or 8 weeks, the mice were euthanized by inhal-
ation of an overdose of carbon dioxide gas. Sample sizes
for calvaria implantations were as follows: 4 weeks
empty, n =3; 4 weeks BCP, n =3; 4 weeks BCP + BMSCs,
n =4; 8 weeks empty, n =3; 8 weeks BCP, n =6; and
8 weeks BCP + BMSCs, n =5.
Decalcified histology preparation, staining and
histomorphometry
Explants were observed for signs of tissue necrosis, in-
flammation or infection, dissected and fixed in 10 volumes
of buffered 4% formaldehyde for 72 hours. The skulls were
further dissected using a diamond saw. Explants were dec-
alcified in 4.13% ethylenediamine tetraacetic acid/0.2%
paraformaldehyde in phosphate-buffered saline, pH 7.4 for
96 hours at 50°C using an automated microwave decalcify-
ing apparatus (KOS Histostation; Milestone Medical,
Kalamazoo, Michigan, USA). Samples were then dehy-
drated in ascending series of ethanol baths (80, 95 and
100%) and finally in butanol for 30 minutes in an auto-
mated dehydration station (Microm Microtech, Lyon,
France). Samples were then impregnated in liquid paraffin
at 56°C (Histowax; Histolab, Gottenburg, Sweden) and
embedded at −16°C. Blocks were cut using a standard
microtome (Leica RM2255; Leica Biosystems, Nanterre,
Ile-de-France, France). Thin histology sections (3 to 5 μm
thick) were made perpendicular to the plane of the skin for
subcutis implants and in the middle of calvaria defects. Sec-
tions were stained by Masson trichrome technique using
an automated coloration station (Microm Microtech). Thisstaining combined hematoxylin for cell nuclei (blue/black),
fuchsine for cytoplasm, muscle and erythrocytes (red), and
light green solution for collagen (green). Stained slices were
scanned (NanoZoomer; Hamamatsu, Photonics, Hamamatsu
City, Shizuoka Prefecture, Japan) and observed with the
virtual microscope (NDP view; Hamamatsu). Histomor-
phometry of images were processed on the whole im-
plant sections using Image J software (National Institute
of Health, Bethesda, Maryland, USA) and the percentage
areas of biomaterial, bone tissue, and bone marrow per
implant were calculated.
Nondecalcified histology and backscattered scanning
electron imaging
Fixed explants were dehydrated in ascending graded
ethanol series followed by one bath of pure acetone and
then impregnated with methylmethacrylate for 4 days at
4°C. Each resulting block was cut in half with a circular
diamond saw (Leica SP1600) and polished with 4,000-
grit silicon carbide sandpaper. Samples were sputtered
with a thin layer of gold–palladium (JEOL JFC - 1100E;
JEOL, Akishima, Japan) and backscattered electron im-
ages were taken using a scanning electron microscope,
operating at an accelerating voltage of 15 kV (HITACHI
TM-3000; HITACHI, Tokyo, Japan).
In situ hybridization
In situ hybridization using the human-specific repetitive
Alu sequence, which comprises approximately 5% of the
total human genome, was performed for identification of
human cells as described previously [27] with minor
changes. Analysis was performed on ectopic explants of
50 mg BCP particles with or without 2 × 106 of passage 2
BMSCs. Briefly, sections were treated with 3% hydrogen
peroxide for 15 minutes at room temperature, then with
10 μg/ml proteinase K (Sigma-Aldrich, Lyon, France) for
10 minutes at 37°C, followed by 0.25% acetic acid in 0.1 M
triethanolamine, pH 8.0 for 20 minutes at room
temperature. Prehybridization was performed for 3 hours
at 56°C in a hybridization buffer containing 4× SSC
(Sigma-Aldrich), 50% deionized formamide, 1× Denhardt’s
solution, 5% dextran sulfate, 100 μg/ml salmon sperm
DNA and molecular-grade water. Hybridization buffer
was refreshed with the addition of 70 nM custom
DIG-labeled human locked nucleic acid Alu probe 5DigN/
5′-TCTCGATCTCCTGACCTCATGA-3′/3DigN (Exiqon,
Vedbaek, Denmark) and then target DNA and the probe
were denatured for 5 minutes at 95°C. Hybridization was
carried out for 19 hours at 56°C. The hybridized probe
was detected by immunohistochemistry using biotin-SP-
conjugated IgG fraction monoclonal mouse anti-digoxin
(Jackson Immunoresearch, West Grove, Pennsylvania,
USA) diluted 1/200 in Tris-buffered saline with Tween,
2% bovine serum albumin for 35 minutes at 37°C.
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withTween) for 45 minutes at 37°C before diaminobenzidine
substrate addition (Dako, Les Ulis, Ile-de-France, France).
Sections were counterstained with Gill-2 hematoxylin
(Thermo Shandon Ltd, Runcorn, UK).
Bioluminescence imaging of luciferase-expressing BMSCs
To monitor the biological activity of BMSCs implanted sub-
cutaneously, BMSCs were genetically modified using lenti-
viral units to co-express luciferase and green fluorescent
protein (eGFP) reporter genes as described previously [28].
Briefly, cells were amplified in alpha minimum essential
medium supplemented with 8% human PL, 100 U/ml peni-
cillin and 100 μg/ml streptomycin, 1 U/ ml heparin and
1 ng/ml basic fibroblast growth factor. The percentage of
luciferase and eGFP expressing cells (Luc/eGFP MSCs) was
quantified by measuring the eGFP expression by flow cy-
tometry (FC-500 Flow cytometer; Beckman Coulter, Nyon,
Switzerland). Luciferase activity was measured for 1 × 105 cells
in a 96-well plate with 100 μl lysis substrate buffer (Steady-Glo
Luciferase Assay; Promega, Charbonnieres-les Bains,
France) and 100 μl culture medium using a VICTOR
plate reader (Perkin Elmer, Waltham, Massachusetts,
USA). Cells in passage 8 were used for bioluminescence
imaging (BLI) experiments. The experimental group
consisted of 1 × 106 Luc/eGFP MSCs in unison with
25 mg BCP implanted subcutaneously in nude mice
(n =6) as described above. A control group consisted of a
subcutaneous injection of 1 × 106 Luc/eGFP MSCs on the
right dorsal side of mice and 25 mg BCP implanted alone
on the left dorsal side (n =6). Luciferase activity was moni-
tored at days 0, 2, 4, 8, 11, 14, 18, 21, 28 and 37 using a
photon imager (Biospace, Paris, France). Before each ac-
quisition, 3 mg luciferin-D in 250 μl distilled, sterile water
was injected intraperitoneally. The BLI results are
expressed as counts per minute.
Statistical analysis
All experiments were blinded and data are expressed as
mean ± standard error of the mean. Statistical comparison
between groups was performed using a one-way analysis
of variance. Minitab statistical software was used (Minitab
16; Minitab Ltd, Coventry, UK). Statistical significance
was set as P <0.05.
Results
Bone marrow stromal cell production and
characterization
Several batches of BMSCs were isolated from bone marrow
and expanded in GMP conditions using PL as a fetal calf
serum alternative. After only one passage several hundred
million BMSCs were consistently produced, as reported
previously [6]. The BM-MNC content was 10.47 × 106 ±
4.43 × 106/ml. The CFU-F content was 357 ± 155 CFUs/106BM-MNCs. The CFU-F content in aspirates performed
(about 3,738/ml bone marrow aspirate) is therefore well
above the described range by Cuthbert and colleagues [29],
confirming high-quality bone marrow aspirates were ob-
tained. Furthermore, the doubling times of the BMSCs
from each of the donors used for ectopic bone formation
(Donors 1 to 5) and from the donors used for calvaria re-
generation (Donors 6 to 8) are presented in Table 1. Pheno-
typic characterization of BMSCs by flow cytometry is
presented in Figure 1a and showed that >90% of BMSCs
expressed surface markers CD73, CD90, CD105 and HLA
A-B-C, and <5% expressed surface markers CD3, CD34,
CD45 and HLA DP,DQ,DR. Confirmation of the adipo-
genic, chondrogenic and osteogenic in vitro differentiation
capacity of BMSCs is presented in Figure 1b.
Optimal cell dosage for bone formation
An initial objective of this study was to determine the
number of cells required for bone formation. Different
quantities of cells, in unison with BCP particles, were
therefore implanted subcutaneously in nude mice. Bone
and bone marrow were quantified after 8 weeks and pre-
sented as a percentage of the total implant cross-
sectional area. As illustrated in Figure 2, no bone forma-
tion was demonstrated in either the 0 or and 0.1 × 106
cell groups. Conversely, both the 2 × 106 (13.30 ± 3.23)
and 4 × 106 (16.54 ± 3.33) cell groups formed signifi-
cantly more bone compared with both the 0 and 0.1 ×
106 cell groups (P <0.02). There was no significant differ-
ence in the quantity of bone formed between the 2 × 106
and 4 × 106 cell groups. Bone marrow territories were
present only in the 2 × 106 (0.51 ± 0.47) and 4 × 106
(0.97 ± 0.77) cell groups, but the difference between
groups did not reach statistical significance. Based on
these results the optimal cell dosage was set at 2 × 106
cells/50 mg BCP. Since 1 cm3 BCP weighs 500 mg, this
cell dosage translates to 20 × 106 cells/cm3 biomaterial.
Viability following transportation of clinical batches of
fresh BMSCs
The determined optimal cell dosage of 20 × 106 cells/cm3
biomaterial translates to 100 × 106 BMSCs for filling clin-
ically relevant sized bone defects of 5 cm3. Syringes con-
taining 100 × 106 BMSCs were shipped from Germany
within 24 hours and the cell viability was determined
upon arrival in France. As presented in Figure 3, the aver-
age percentage cell viability upon arrival in syringes with
4% HSA was 69.9 ± 9.55%, with 5% HSA was 69.15 ±
5.43% and with 20% HSA was 87.27 ± 5.26%, with no stat-
istical difference between transportation media. Syringes
containing the BMSCs and biomaterial are shown in
Figure 3a,b,c,d. A standard operating procedure was
developed for mixing cells and biomaterial under asep-
tic condition in the surgical room for 1 hour. It was
Table 1 Doubling times of bone marrow stromal cells used for bone formation assessment
Donor 1 2 3 4 5 6 7 8
Passage 0 doubling time (hours) 20.8 21.5 20.4 21.8 20.2 27.0 27.8 26.4
Passage 1 doubling time (hours) 48.4 35.1 39.7 33.1 34.8 39.6 60.2 39.3
Passage 0 number of population doublings 12.1 11.2 11.7 10.9 11.7 12.4 12.1 12.6
Passage 1 number of population doublings 2.4 3.3 3.0 3.5 3.3 4.2 2.8 4.2
Cumulative population doublings 14.5 14.5 14.7 14.4 15.0 16.6 14.9 16.8
Protocol option as published by Fekete and colleagues [6] 2 2 2 2 2 1 1 1
Donors 1 to 5, ectopic; Donors 6 to 8, calvaria.
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pended in HSA attached to BCP particles after 1 hour
[17]. Although we found that the maximal cell attach-
ment was attained at approximately 4 hours after seed-
ing, a 1-hour attachment time was chosen for theFigure 1 Characterization of bone marrow stromal cells. (a) Represent
practice-grade bone marrow stromal cells (BMSCs) by flow cytometry. More
and <5% of cells had surface antigen expression for CD3, CD34, CD45 and
Adipogenic (Oil Red O/hematoxylin staining), chondrogenic (Alcian blue st
induced, whereas no differentiation could be observed in controls without
500 μm for osteogenic differentiation, and 1,000 μm for chondrogenic.preclinical and clinical trials because this time frame is
appropriate in the surgical setting. As shown by methy-
lene blue staining (Figure 3f ), this procedure guaranteed
adequate attachment and even distribution of BMSCs
on the BCP granules prior to implantation.ative results of phenotypic characterization of good manufacturing
than 90% of BMSCs express CD73, CD90, CD105 and HLA A-B-C,
HLA DP, DQ, DR. (b) Tri-lineage differentiation capacity was confirmed.
aining) and osteogenic differentiation (Alizarin red staining) could be
induced of differentiation. Black scale bars: 250 μm for adipogenic,
Figure 2 Optimal cell dosage for ectopic bone formation. (a) Masson trichrome staining shows biphasic calcium phosphate biomaterial
(BCP, gray) in contact with newly formed bone (B, green). Mature bone marrow territories (BM) were present after 8 weeks. Scale bars: 2.5 mm
and 250 μm for images in the left and right columns respectively. (b) Histomorphometry revealed significantly more bone in the 2 × 106 to 4 × 106 cell
groups compared with the empty scaffolds (aP <0.02) and compared with the 0.1 × 106 cell group (bP <0.02). (c) Bone marrow territories were present
only in the 2 × 106 and 4 × 106 cell groups, but there was no statistical difference between groups. BMSCs, bone marrow stromal cells.
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Figure 3 Transportation of fresh bone marrow stromal cells. (a) to (d) Syringes containing 100 million bone marrow stromal cells (BMSCs)
were transported from Germany to France where they were mixed with biphasic calcium phosphate (BCP) biomaterial in sterile syringes. (e) No
difference in viability of transported cells according to the percentage of human serum albumin (HSA) in the transportation media was found
upon arrival in France. (f) Methylene blue staining shows cells attached to the BCP particles after 1 hour.
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several batches of BMSCs
The ectopic model was performed to demonstrate the
osteoinduction of the BMSC/BCP combination of
seven GMP batches from five human donors that
were transported fresh. The subcutis implantations in
nude mice showed a thin fibrous tissue capsule with
abundant vascularization without sign of tissue necro-
sis, local inflammation or infection. After 8 weeks, no
ectopic bone formation was observed in control
groups with BCP biomaterial alone (data not shown).
In contrast, in the BCP + BMSCs group, ectopic bone
formation was observed at the periphery of the explants
and demonstrated a well-mineralized lamellar bone
tissue with osteocyte lacunae, as illustrated by back-
scattered electron microscopy and Masson trichrome
staining in Figure 4a,b,c. The percentage of bone forma-
tion revealed significant differences in the bone induc-
tion capacity between human donors, as presented in
Figure 4d.Regeneration of critical size defects in calvaria of nude
mice
To investigate the potential of BMSCs to regenerate
bone defects, BMSCs were implanted with BCP discs
over critical-sized cranial defects. Defects that were
either left empty or overlain with BCP biomaterial alone
served as controls. All animals recovered well from
surgery without signs of neurological damage. As shown
in Figure 5a,b,c, no statistical difference in percentage of
bone or bone marrow formation within the BCP discs
was found between the BCP and BCP + BMSCs groups
4 weeks after implantation; however, a trend towards
increased bone formation in the BCP + BMSCs group
was observed (P <0.088). After 8 weeks, the percentage of
bone formation was significantly higher in scaffolds with
BMSCs (37.41 ± 8.93%) than BCP scaffolds alone (1.58 ±
0.51%) (P <0.02; Figure 5b). Likewise, bone marrow
presence was higher in the BCP + BMSCs group after
8 weeks (5.56 ± 1.95%) compared with the BCP group
(no bone marrow presence) (P <0.05; Figure 5c). Empty
Figure 4 Ectopic bone formation of freshly transported batches of bone marrow stromal cells. (a), (b) In backscattered electron imaging,
the biphasic calcium phosphate (BCP) ceramic and mineralized bone can be differentiated by their relative gray densities. The BCP particles were
surrounded by a well-mineralized lamellar bone tissue in the BCP + BMSCs group after 8 weeks. (c) Masson trichrome staining showed bone
formation (B) at the periphery of the explants that contained bone marrow compartments (BM). (d) Histomorphometry of Masson trichrome
staining sections revealed significant differences in the bone induction capacity between human donors. aStatistically lower compared to
Donor 4 (P <0.05). bStatistically lower compared with to Donor 5 (P <0.05). BMSCs, bone marrow stromal cells.
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age of defect closure was 26.29 ± 14.29% after 4 weeks
and 26.97 ± 9.53% after 8 weeks) and were filled with
fibrous tissue, confirming that the model was a critical-
sized bone defect. Defect closure with BCP scaffolds
alone was 35.75 ± 5.08% after 4 weeks and 45.25 ±
7.01% after 8 weeks. Some BCP + BMSCs samples
achieved complete defect closure, as shown in Figure 5a.
Most, however – especially those with significant bone
formation within the biomaterial scaffold – did not
achieve complete defect closure; rather, a bone bridging
was accomplished by the bone-filled scaffold overlying
the defect. Defect closure of BCP scaffolds with BMSCs
was 40.50 ± 11.01% after 4 weeks and 55.15 ± 12.09%
after 8 weeks; this was not statistically higher than the
other groups however.
Bioluminescence imaging of luciferase-expressing BMSCs
To assess the survival capacity and biological activity of
BMSCs following implantation in vivo, BLI was per-
formed on Luc/eGFP MSCs transplanted in nude mice.
As depicted in Figure 6a,b, in the subcutaneous injection
control group the BLI signal was 63,371.43 ± 4,396.13 atday 4, after which the signal dramatically decreased: at
day 28 only 3/6 mice had a detectable BLI signal (3.41 ±
1.90) and no signal was present at day 37. In the expe-
rimental group (BCP + BMSCs), the BLI signal also re-
duced throughout the duration of the experiment;
however, it was a much less striking decline compared
with the subcutaneous injection control group, as seen
in Figure 6b. BCP particles dampen the BLI signal, as ev-
idenced from Figure 6b, since the same quantity of cells
was transplanted into both groups at day 0 but the BLI
signal in the BCP + BMSCs group was significantly lower
than that of the subcutaneous injection group (5,184 ±
622.96 vs. 84,082.61 ± 10,478.04, P <0.05). Figure 6c il-
lustrates the percentage of the original signal at day 0
remaining at each time point. At day 8 there was a sig-
nificantly higher percentage of initially transplanted cells
remaining in the BCP + BMSCs group, compared with
the subcutaneous injection group (54.72 ± 12.69 vs. 8.89
± 3.78, P <0.01). This observation was corroborated at
every later time point. By day 37, 1.57 ± 0.63% of the ini-
tial BLI signal remained in the BCP + BMSCs group,
while there was no signal remaining in any of the sub-
cutaneous injection mice.
Figure 5 Regeneration of critical size defects in calvaria of nude mice. (a) Masson trichrome staining (MT) of calvaria defects after 8 weeks
shows bone in green and biphasic calcium phosphate (BCP) in gray. Scale bars: 2.5 mm and 500 μm for images in the left and right columns
respectively. (b), (c) Histomorphometry of MT sections revealed that there was significantly more (aP <0.05) newly formed bone and bone
marrow formed with the scaffolds of the BCP + BMSCs group compared with BCP discs without cells. BMSCs, bone marrow stromal cells.
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In situ hybridization using the human-specific repeti-
tive Alu sequence allowed for the identification of
human cells in explants. As evidenced in Figure 7,
after 8 weeks of implantation, it was observed that
while most of the explants were comprised of host
cells (purple nuclei), there were also human cellspresent (brown/black nuclei). Few human cells were
present in the fibrous tissue, while more human cells
were identified attached along the periphery of BCP
particles. Furthermore, human osteocytes were found
embedded in lacunae dispersed throughout the bone
matrix with osteocytes of mice origin in close
proximity.
Figure 6 Bioluminescence imaging of luciferase-expressing bone marrow stromal cells. (a) Representative bioluminescence imaging (BLI)
for a control group that received biphasic calcium phosphate (BCP) alone on their left dorsal side and subcutaneous (SC) injections of bone
marrow stromal cells (BMSCs) on their right dorsal side, and the experimental group that received subcutis implantations of BCP + BMSCs. (b) The
BLI signal, expressed as counts per minute (cpm), decreased after transplantation, while BCP dampened the BLI signal. (c) When the number of
remaining cells compared with the number of initially transplanted cells was expressed at each time point, SC implantation of BCP + BMSCs was
significantly higher from day 8 onwards compared with the SC injections group (aP <0.01). Approximately 1.5% of the initial number of
transplanted cells in the SC BCP + BMSCs group remained at day 37.
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Repair of bone defects remains a significant clinical chal-
lenge. In this study, 100 million BMSCs were trans-
ported in each syringe from a GMP facility in Germany
to another site in France where they were mixed with
biomaterial and implanted, mimicking the clinical sce-
nario where large bone defects shall be regenerated.
Bone containing mature bone marrow territories was
formed in ectopic sites and in calvaria defects. Followingimplantation, the human cell number was drastically re-
duced; nevertheless, by 8 weeks some human cells were
observed in osteocyte lacunae in newly formed bone.
It was important to investigate the optimal cell dosage
for implantation in this study since, for clinical relevance,
implanting too few cells would yield inadequate bone heal-
ing, while implanting more cells than required would re-
sult in cell wastage and more prolonged in vitro expansion
times. A sharp increase in bone formation was found from
Figure 7 In situ hybridization using the human-specific repetitive Alu sequence for identification of human cells. All samples were
analyzed after 8 weeks of subcutaneous implantation in nude mice (a) Negative control. (b) Although explants were composed primarily of
mouse cells (purple nuclei), human cells (brown/black) were identified attached along the periphery of biphasic calcium phosphate (BCP)
particles (red arrows). These regions of interest are shown in magnified view. (c) Masson trichrome staining of explants with a serial section
showing human cells present (red arrow), with a magnified view also presented. (d) Explant showing mice cells (purple nuclei) and human cells
(brown/black nuclei) embedded in osteocyte lacunae and surrounding BCP particles (red arrows). Scale bars: 250 μm. B, bone formation.
Brennan et al. Stem Cell Research & Therapy 2014, 5:114 Page 12 of 15
http://stemcellres.com/content/5/5/1140.1 × 106 cells per implant to 2 × 106 cells per implant.
Interestingly, doubling the cell density to 4 × 106 cells did
not yield significantly more bone or bone marrow territor-
ies, demonstrating that a threshold was reached beyond
which more implanted cells did not yield more bone for-
mation. This result is in agreement with a previous study
[12]. The ratio of cells to weight of biomaterial was then
scaled up to a clinically equivalent dosage of 100 × 106BMSCs per 5 cm3 of BCP granules. A standard operating
procedure for mixing cells and biomaterial before implant-
ation was developed. Bone formation was evaluated at
8 weeks since it has been shown previously that there is
only minimal bone formation prior to this duration [12].
The percentage of HSA in the transportation media was
reduced from 20% because it favored the formation of cell
aggregates. The rationale for including both 4% and 5%
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France whereas 5% HSA is commercially available in
Germany. Due to the large heterogeneity between human
donors, it was not possible to assess whether the HSA con-
centration affected bone formation. However, independ-
ently of the percentage of HSA, the cell viability after
transportation was approximately 70% and it is expected
that this would be even higher in the clinical scenario due
to the closer proximity of GMP production sites to the
operating room. Cells attached to the BCP scaffold after
only 1 hour and this is a clinically compatible preparation
time for surgery of patients. Cells were transported at 20°C
in this study; however, it must be noted that 4°C was since
found to be a more optimal temperature [17].
Mature bone, including the presence of bone marrow
territories, was observed after 8 weeks in subcutis ex-
plants. Hematopoiesis was only observed in explants
with significant bone formation. This timing is well in
agreement with other reports describing ectopic bone
formation [18,19]. The transplants devoid of implanted
BMSCs did not achieve any bone formation. Further-
more, this study demonstrated that human BMSCs
could form bone and aid healing of critical-sized calvaria
defects after 8 weeks. Abundant bone was formed within
the BCP discs with mature bone marrow territories,
which is relevant for maxillofacial regeneration.
The significant variability in the bone formation cap-
acity between human donors is in agreement with previ-
ous studies [30,31]. Age, gender, disease and medications
have been associated with altered prevalence of BMSCs
in bone marrow as well as their activity in vitro [32-34].
In the current study, BMSCs were attained from healthy
human donors ranging in age from 21 to 26, so age or
disease was not a factor here. In addition, there was no
correlation found between the bone formation capacity
of the BMSCs from the five donors used for ectopic
bone formation and the colony-forming efficiency of the
bone marrow aspirates, expressed as CFUs-F/10 × 106
MNCs (data not shown). Others found that there was
no correlation between gender and bone formation cap-
acity [30]. Understanding the underlying factors respon-
sible for donor variability is of paramount importance
for the clinical application of BMSCs for bone regener-
ation and will be the focus of future investigations.
In this study, the fate of the implanted cells in sub-
cutaneous sites in the early and late stages of engraft-
ment was evaluated using both bioluminescence imaging
and in situ hybridization for the human-specific Alu se-
quence. We observed significant loss of the BLI signal
over the experiment duration, with only approximately
1.5% of transplanted cells remaining after 37 days. It
must be noted, however, that since the Luc/eGFP MSCs
used for the bioluminescence imaging were in passage 8,
this could have possibly contributed to their earlydisappearance due to higher doubling times that accom-
pany high passage numbers. Nevertheless, this finding is in
agreement with other studies noting a large loss of trans-
planted BMSCs [24,25]. Furthermore, although the BCP
particles reduced the BLI signal intensity of BMSCs, the
reliability of BLI for determining viable cell numbers was
previously confirmed with BCP and BMSCs [24].
At 8 weeks, using in situ hybridization for the human-
specific Alu sequence (BMSCs implanted at passage 2),
it was observed that there were some human cells found
along the periphery of the BCP particles and embedded
in osteocyte lacunae; however, the vast portion of cells
present were of host origin. A previous study also found
donor cells present in newly formed bone tissue [13].
However, in other studies no implanted BMSCs were ob-
served in newly formed bone and host cells were directly
responsible for bone formation [23,35,36]. There could
be numerous reasons for these conflicting observations
between studies, including the methods of ex vivo ex-
pansion (fetal calf serum vs. PL), the type of scaffold
used (some scaffolds are better than others at retaining
BMSCs), and even the strain of recipient mice (how im-
mune deficient they are). The primary factors respon-
sible for the large cell death of transplanted BMSCs
include the ischemic environment [25] and the lack of
glucose that the BMSCs encounter [37]. Despite this
substantial cell death, the transplanted BMSCs mediated
bone formation by host BMSCs, suggesting that trans-
planted BMSC-secreted paracrine molecules may play
an important role in bone formation by host BMSCs.
It has been shown previously that BMSC modulation
of the foreign body reaction and interaction with the
host immune cells play a role in BMSC-mediated bone
formation [36]. Furthermore, we have recently demon-
strated the role of BMSCs as mediators rather than ef-
fectors of bone formation by impacting the foreign body
reaction [38]. BMSCs attracted circulating hematopoietic
stem cells and prompted their differentiation into mac-
rophages M1 and osteoclasts; ablation of osteoclastogen-
esis largely inhibited BMSC-mediated bone formation
[38]. However, at present, the precise mechanisms of
how donor BMSCs recruit host BMSCs to the site is un-
certain and warrants further investigation.
In this study, BMSCs have been successfully expanded,
transported and implanted for bone repair, mimicking a
clinically relevant scenario. In unison with BCP biomaterial,
BMSCs achieved ectopic bone formation with bone
marrow territories and successfully repaired critical-sized
cranial defects. A drastic loss of BMSC viability after
transplantation was observed. Newly formed bone con-
tained some cells of human origin, but explants were pri-
marily composed of host cells. This study demonstrates
the safety and efficacy of BMSC/BCP combinations for
bone regeneration.
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Our findings provide therapeutic evidence that BMSC/
BCP associations may be used for bone regeneration and
present crucial information for the implementation of
human BMSC therapy in clinical practice for the treat-
ment of nonunion fractures.
Abbreviations
BCP: biphasic calcium phosphate; BLI: bioluminescence imaging; BM-MNC:
bone marrow mononuclear cell; BMSC: bone marrow stromal cell;
CFU-F: colony-forming unit; GFP: green fluorescent protein; GMP: good
manufacturing practice; HSA: human serum albumin; PL: plate lysate.
Competing interests
MTR and HS work for a nonprofit organization that is manufacturing platelet
lysate. The remaining authors declare that they have no competing interests.
Authors’ contributions
MAB performed project planning, data collection, analysis and interpretation,
and drafted the manuscript. AR participated in project planning and carried
out the in vivo experiments. JA conducted histology and staining and
collected data. MTR participated in project planning, data collection, analysis
and interpretation. HS participated in project planning, and data collection,
analysis and interpretation. DH participated in manuscript writing and
provided administrative support. VT participated in project planning, data
analysis and interpretation and manuscript writing. PL designed and
supervised the experiments, and performed data interpretation and
manuscript writing. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the 7th Framework Program of the
European Commission: CASCADE (Cultivated Adult Stem Cells as Alternative
for Damaged tissuE) (HEALTH-F5-2009-223236) and REBORNE (Regenerating
BOne defects using New biomedical Engineering approaches) (HEALTH-
2009-1.4.2-241879). The authors appreciate the excellent technical assistance
of G Baur, T Becker, S Chester, D Erz, and C Späth.
Author details
1INSERM, UMR957, Laboratory of the Pathophysiology of Bone Resorption, Faculty
of Medicine, 1 Rue Gaston Veil, 44035, University of Nantes, Nantes, France.
2Institute for Clinical Tranfusion Medicine and Immunogenetics, German Red
Cross Blood Donor Service, Ulm, Germany.
Received: 21 May 2014 Revised: 30 September 2014
Accepted: 30 September 2014 Published: 13 October 2014
References
1. Giannoudis PV, Dinopoulos H, Tsiridis E: Bone substitutes: an update. Injury
2005, 36:S20–S27.
2. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD,
Moorman MA, Simonetti DW, Craig S, Marshak DR: Multilineage potential
of adult human mesenchymal stem cells. Science 1999, 284:143–147.
3. Caplan AI: The mesengenic process. Clin Plast Surg 1994, 21:429–435.
4. European Commisson: Regulation (EC) No 1394/2007 of the European
Parliament and of the Council of 13 November 2007 on advanced
therapy medicinal products and amending directive 2001/83/ and
Regulation (EC) No 726/2004. Off J Eur Union 2007, 50:121–137.
5. Fekete N, Gadelorge M, Fürst D, Maurer C, Dausend J, Fleury-Cappellesso S,
Mailänder V, Lotfi R, Ignatius A, Sensebé L, Bourin P, Schrezenmeier H,
Rojewski MT: Platelet lysate from whole blood-derived pooled platelet
concentrates and apheresis-derived platelet concentrates for the isola-
tion and expansion of human bone marrow mesenchymal stromal cells:
production process, content and identification of active components.
Cytotherapy 2012, 14:540–554.
6. Fekete N, Rojewski MT, Fürst D, Kreja L, Ignatius A, Dausend J,
Schrezenmeier H: GMP-compliant isolation and large-scale expansion of
bone marrow-derived MSC. PLoS One 2012, 7:e43255.
7. Schallmoser K, Rohde E, Bartmann C, Obenauf AC, Reinisch A, Strunk D:
Platelet-derived growth factors for GMP-compliant propagation of
mesenchymal stromal cells. Biomed Mater Eng 2009, 19:271–276.8. Schallmoser K, Rohde E, Reinisch A, Bartmann C, Thaler D, Drexler C, Obenauf
AC, Lanzer G, Linkesch W, Strunk D: Rapid large-scale expansion of functional
mesenchymal stem cells from unmanipulated bone marrow without animal
serum. Tissue Eng Part C Methods 2008, 14:185–196.
9. Crespo-Diaz R, Behfar A, Butler GW, Padley DJ, Sarr MG, Bartunek J, Dietz AB,
Terzic A: Platelet lysate consisting of a natural repair proteome supports
human mesenchymal stem cell proliferation and chromosomal stability.
Cell Transplant 2011, 20:797–811.
10. Chevallier N, Anagnostou F, Zilber S, Bodivit G, Maurin S, Barrault A,
Bierling P, Hernigou P, Layrolle P, Rouard H: Osteoblastic differentiation of
human mesenchymal stem cells with platelet lysate. Biomaterials 2010,
31:270–278.
11. Livingston TL, Gordon S, Archambault M, Kadiyala S, McIntosh K, Smith A,
Peter SJ: Mesenchymal stem cells combined with biphasic calcium
phosphate ceramics promote bone regeneration. J Mater Sci Mater Med
2003, 14:211–218.
12. Mankani MH, Kuznetsov SA, Robey PG: Formation of hematopoietic
territories and bone by transplanted human bone marrow stromal cells
requires a critical cell density. Exp Hematol 2007, 35:995–1004.
13. Fang D, Seo B-M, Liu Y, Sonoyama W, Yamaza T, Zhang C, Wang S, Shi S:
Transplantation of mesenchymal stem cells is an optimal approach for
plastic surgery. Stem Cells 2007, 25:1021–1028.
14. Liu G, Shu C, Cui L, Liu W, Cao Y: Tissue-engineered bone formation
with cryopreserved human bone marrow mesenchymal stem cells.
Cryobiology 2008, 56:209–215.
15. François M, Copland IB, Yuan S, Romieu-Mourez R, Waller EK, Galipeau J:
Cryopreserved mesenchymal stromal cells display impaired
immunosuppressive properties as a result of heat-shock response
and impaired interferon-γ licensing. Cytotherapy 2012, 14:147–152.
16. Hunt CJ: Cryopreservation of human stem cells for clinical application:
a review. Transfus Med Hemother 2011, 38:107–123.
17. Veronesi E, Murgia A, Caselli A, Grisendi G, Piccinno MS, Rasini V, Giordano
R, Montemurro T, Bourin P, Sensebe L, Rojewski MT, Schrezenmeier H,
Layrolle P, Ginebra MP, Panaitescu CB, Gomez-Barrena E, Catani F, Paolucci
P, Burns JS, Dominici M: Transportation conditions for prompt use of
ex vivo expanded and freshly harvested clinical-grade bone marrow
mesenchymal stromal/stem cells for bone regeneration. Tissue Eng Part C
Methods 2014, 20:239–251.
18. Mankani MH, Kuznetsov SA, Fowler B, Kingman A, Robey PG: In vivo bone
formation by human bone marrow stromal cells: effect of carrier particle
size and shape. Biotechnol Bioeng 2001, 72:96–107.
19. Arinzeh TL, Tran T, Mcalary J, Daculsi G: A comparative study of biphasic
calcium phosphate ceramics for human mesenchymal stem-cell-induced
bone formation. Biomaterials 2005, 26:3631–3638.
20. Bruder SP, Kurth AA, Shea M, Hayes WC, Jaiswal N, Kadiyala S: Bone
regeneration by implantation of purified, culture-expanded human
mesenchymal stem cells. J Orthop Res 1998, 16:155–162.
21. Muraglia A, Martin I, Cancedda R, Quarto R: A nude mouse model for
human bone formation in unloaded conditions. Bone 1998, 22:131S–134S.
22. Mankani MH, Kuznetsov SA, Wolfe RM, Marshall GW, Robey PG: In vivo
bone formation by human bone marrow stromal cells: reconstruction of
the mouse calvarium and mandible. Stem Cells 2006, 24:2140–2149.
23. Tasso R, Augello A, Boccardo S, Salvi S, Caridà M, Postiglione F, Fais F, Truini
M, Cancedda R, Pennesi G: Recruitment of a host’s osteoprogenitor cells
using exogenous mesenchymal stem cells seeded on porous ceramic.
Tissue Eng Part A 2009, 15:2203–2212.
24. Giannoni P, Scaglione S, Daga A, Ilengo C, Cilli M, Quarto R: Short-time
survival and engraftment of bone marrow stromal cells in an ectopic
model of bone regeneration. Tissue Eng Part A 2010, 16:489–499.
25. Becquart P, Cambon-Binder A, Monfoulet L-E, Bourguignon M, Vandamme
K, Bensidhoum M, Petite H, Logeart-Avramoglou D: Ischemia is the prime
but not the only cause of human multipotent stromal cell death in
tissue-engineered constructs in vivo. Tissue Eng Part A 2012, 18:2084–2094.
26. Krebsbach PH, Mankani MH, Satomura K, Kuznetsov SA, Robey PG: Repair of
craniotomy defects using bone marrow stromal cells. Transplantation
1998, 66:1272–1278.
27. Steck E, Burkhardt M, Ehrlich H, Richter W: Discrimination between cells of
murine and human origin in xenotransplants by species specific
genomic in situ hybridization. Xenotransplantation 2010, 17:153–159.
28. Rousseau J, Escriou V, Perrot P, Picarda G, Charrier C, Scherman D, Heymann
D, Rédini F, Trichet V: Advantages of bioluminescence imaging to follow
Brennan et al. Stem Cell Research & Therapy 2014, 5:114 Page 15 of 15
http://stemcellres.com/content/5/5/114siRNA or chemotherapeutic treatments in osteosarcoma preclinical
models. Cancer Gene Ther 2010, 17:387–397.
29. Cuthbert R, Boxall SA, Tan HB, Giannoudis PV, McGonagle D, Jones E:
Single-platform quality control assay to quantify multipotential stromal
cells in bone marrow aspirates prior to bulk manufacture or direct
therapeutic use. Cytotherapy 2012, 14:431–440.
30. Janicki P, Boeuf S, Steck E, Egermann M, Kasten P, Richter W: Prediction of
in vivo bone forming potency of bone marrow-derived human mesenchymal
stem cells. Eur Cell Mater 2011, 21:488–507.
31. Wagner-Ecker M, Voltz P, Egermann M, Richter W: The collagen component
of biological bone graft substitutes promotes ectopic bone formation by
human mesenchymal stem cells. Acta Biomater 2013, 9:7298–7307.
32. Kučera T, Soukup T, Krs O, Urban K, Sponer P: Bone healing capacity in
patients undergoing total hip arthroplasty. Acta Chir Orthop Traumatol
Cech 2012, 79:52–58.
33. Muschler GF, Nitto H, Boehm CA, Easley KA: Age- and gender-related
changes in the cellularity of human bone marrow and the prevalence of
osteoblastic progenitors. J Orthop Res 2001, 19:117–125.
34. Stenderup K, Justesen J, Clausen C, Kassem M: Aging is associated with
decreased maximal life span and accelerated senescence of bone
marrow stromal cells. Bone 2003, 33:919–926.
35. Corre P, Merceron C, Vignes C, Sourice S, Masson M, Durand N, Espitalier F,
Pilet P, Cordonnier T, Mercier J, Remy S, Anegon I, Weiss P, Guicheux J:
Determining a clinically relevant strategy for bone tissue engineering: an
‘All-in-One’ study in nude mice. PLoS One 2013, 8:e81599.
36. Tour G, Wendel M, Tcacencu I: Bone marrow stromal cells enhance the
osteogenic properties of hydroxyapatite scaffolds by modulating the
foreign body reaction. J Tissue Eng Regen Med 2012, [Epub ahead of print].
37. Deschepper M, Manassero M, Oudina K, Paquet J, Monfoulet L-E, Bensidhoum
M, Logeart-Avramoglou D, Petite H: Proangiogenic and prosurvival functions
of glucose in human mesenchymal stem cells upon transplantation.
Stem Cells 2013, 31:526–535.
38. Gamblin A-L, Brennan MA, Renaud A, Yagita H, Lézot F, Heymann D,
Trichet V, Layrolle P: Bone tissue formation with human mesenchymal stem
cells and biphasic calcium phosphate ceramics: the local implication of
osteoclasts and macrophages. Biomaterials 2014, 35:9660–9667.
doi:10.1186/scrt504
Cite this article as: Brennan et al.: Pre-clinical studies of bone
regeneration with human bone marrow stromal cells and biphasic
calcium phosphate. Stem Cell Research & Therapy 2014 5:114.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
